Related Experiment Video
Updated: Jul 25, 2025
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions
Enrico Sammarco1, Fiorella Manfredi1, Amedeo Nuzzo1
1Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Santa Chiara Hospital, 56126 Pisa, Italy.
Abstract:
Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma. Despite a clear benefit in survival outcomes, a considerable proportion of patients experience disease progression; prospective data about second-line therapy after first-line treatment with immune checkpoint inhibitors are limited to small phase II studies. As with other solid tumors (such as melanoma and non-small cell lung cancer), preliminary data about the clinical efficacy of rechallenge of immunotherapy (alone or in combination with other drugs) in renal cell carcinoma are beginning to emerge. Nevertheless, the role of rechallenge in immunotherapy in this setting of disease remains unclear and cannot be considered a standard of care; currently some randomized trials are exploring this approach in patients with metastatic renal cell carcinoma. The aim of our review is to summarize main evidence available in the literature concerning immunotherapy rechallenge in renal carcinoma, especially focusing on biological rationale of resistance to immune checkpoint inhibitors, on the published data of clinical efficacy and on future perspectives.
Insights
Immune checkpoint inhibitors are standard for advanced renal cell carcinoma, but some patients progress. This review examines immunotherapy rechallenge as a potential second-line treatment, exploring its efficacy and future role.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma
Background:
- Immune checkpoint inhibitors (ICIs) are first-line standard for advanced renal cell carcinoma (RCC).
- Significant patient populations experience disease progression despite ICI therapy.
- Limited data exist on second-line treatments following first-line ICIs in advanced RCC.
Purpose of the Study:
- To review current evidence on immunotherapy rechallenge in advanced renal cell carcinoma.
- To explore the biological rationale for resistance to ICIs.
- To summarize clinical efficacy data and future perspectives of immunotherapy rechallenge in RCC.
Main Methods:
- Literature review of studies on immunotherapy rechallenge in renal cell carcinoma.
- Analysis of biological mechanisms underlying resistance to immune checkpoint inhibitors.
- Synthesis of published clinical efficacy data from phase II studies and ongoing trials.
Main Results:
- Preliminary data suggest potential efficacy of immunotherapy rechallenge in some advanced RCC patients.
- Understanding resistance mechanisms is crucial for optimizing rechallenge strategies.
- Randomized trials are ongoing to clarify the role of rechallenge in metastatic RCC.
Conclusions:
- Immunotherapy rechallenge is an emerging strategy for advanced RCC after initial ICI failure.
- Its role as a standard of care is not yet established, requiring further investigation.
- Ongoing research aims to define the optimal use of rechallenge in refractory RCC.
More Related Videos
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...